DLL3 and neuroendocrine neoplasm: Antibody-drug conjugates are emerging as a method of treatment for malignancies, including MCC.CD56 is a glycoprotein expressed on neuroendocrine tumors, and has been shown to be expressed on MCC tumors.DLL3 has also been proposed as a target for antibody-drug conjugates.